Shoulder bones X ray.
Adobe Stock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

Orthocell (ASX:OCC) shares jumped close to 5% heading into afternoon trade as the company flagged record yearly revenues.

The company sells two keystone products – Striate+ and Remplir respectively – both aimed at regenerating bones and tissue after surgery.

Orthocell clocked record revenues of $1.84M, up 14.4% vs Q3 of FY24.

However, yearly growth was the real boast – full year FY24 revenue clocked $6.72M; a +30.4% increase YoY.

Both products are effectively patches that contain collagen which can then be applied to bones post-surgery to aid healing. Orthocell’s Striate is designed specifically for dental applications whereas Remplir is aimed at healing nerve damage.

Striate+ is sold in the US, EU and UK, Australia and New Zealand. Remplir, meanwhile, is only sold in Australia and NZ – with Orthocell “accelerating approvals to expand into new markets.”

Orthocell stated on Tuesday the total potential market value when it comes to patients requiring such products could be US$3B. While that’s a long way off $6M in revenues, it was enough to partly boost optimism for the stock on Tuesday.

“These results show the Company is on track to being a key global player. I am very pleased with the performance of our distribution partners and the continued increase in product adoption,” Orthocell MD Paul Anderson said.

“With a highly respected and experienced Board in place, and with market-leading products, our Company is in a strong position to continue to gain commercial traction and drive Remplir, our breakthrough nerve repair device, into global markets.”

Orthocell had $20.6M in cash at the end of June according to its Tuesday release.

OCC last traded at 36.5cps.

OCC by the numbers
More From The Market Online
Market Close Graphic

ASX Market Close: More red for Oz investors as 2024 drags into station | Dec 30, 2024

The ASX closed down 0.04% on the second last trading day of 2024, losing three points to drop down to 8,221 as slo…
Money & Investing CEO and founder Andrew Baxter on his programme title page

2024 Year in Review: Key economic trends, market highlights, and investment insights

This week on Money and Investing, Mitch Olarenshaw and I reviewed the major economic, political, and social events that shaped 2024. From record-breaking...
A Maximus Resources mine in the Kambalda Gold Field in Western Australia.

Astral Resources proffers 7c-a-share Maximus Resources takeover to create Kambalda heavyweight

Astral Resources (ASX:AAR) has fired a seven cent-a-share non-binding takeover bid at Kambalda neighbour
A hand holding graphite from a farm.

Last hurdle cleared for Sarytogan after Kazakhstan gov’t gives eponymous graphite project the nod

Mining exploration hopeful Sarytogan Graphite (ASX:SGA) has scored a huge victory as it looks to start work at its